Drugs / Carnosine
Carnosine
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT06480760 | May 2025 → Oct 2028 expected | peripheral arterial disease | Shahid Baba | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05371145 | Mar 2023 → Dec 2024 overdue | peripheral arterial disease | Shahid Baba | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02808624 | Jun 2015 → Nov 2016 | cancer, peripheral neuropathy | Cairo University | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02686697 | Dec 2015 → Jul 2022 | schizophrenia | Abraham Reichenberg | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT00177463 | Sep 2004 → Dec 2007 | bipolar I disorder | University of Pittsburgh | Completed | No outcome recorded |
| — | NCT00177177 | Mar 2004 → Nov 2007 | schizoaffective disorder, schizophrenia | University of Pittsburgh | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT03844113 Comparator | Mar 2019 → Dec 2022 | peripheral arterial disease | Monash University | Unknown | No outcome recorded |
| Phase 2 | NCT04870229 Comparator | May 2016 → Jul 2022 | peripheral arterial disease | University of Louisville | Completed | No outcome recorded |
| Phase 2 | NCT00810368 Comparator | Aug 2008 → Jul 2012 | persian gulf syndrome | Georgetown University | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Carnosine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00810368 ↗ |
| Known as | B-alanyl-L-histidine | “The endogenous antioxidant L-carnosine (B-alanyl-L-histidine) is a potential treatment since it is a free radical scavenger in nervous tissue.” PMID 23618477 ↗ Feb 2013 |
| Known as | beta-alanyl-L-histidine | “Carnosine (beta-alanyl-L-histidine) and homocarnosine (gamma-aminobutyryl-L-histidine) are abundant dipeptides in skeletal muscle and brain of most vertebrates” PMID 20097752 ↗ Jan 2010 |
| Known as | L-carnosine | “The endogenous antioxidant L-carnosine (B-alanyl-L-histidine) is a potential treatment since it is a free radical scavenger in nervous tissue.” PMID 23618477 ↗ Feb 2013 |
| Known as | β-alanine-histidine | “supplementation of carnosine(β-alanine-histidine) (500 mg/day) in heart failure patients for 6 months improves their performance” NCT05371145 ↗ |
| Action | Inhibit | “an antioxidant and AGE inhibitor” NCT00177463 ↗ |
| Modality | Peptide | “a naturally occurring dipeptide” NCT00177177 ↗ |
| Route | Oral | “oral L-carnosine treatment” NCT00177177 ↗ |
| Target | HIF1A | “through stabilisation of HIF1-α in the ischaemic leg” NCT03844113 ↗ |